In the News - View AAM CEO Dan Leonard's blog on the essential role generic drugs play during COVID-19

Congress Can Help to Secure Our Meds

Generic and biosimilar medicines are essential to treating millions of patients. Together, we can take steps to secure patient access no matter what challenges may arise.

Learn More
Plan to Secure Our Medicines

The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to #SecureOurMeds. We already produce billions of doses domestically and our plan ensures continued patient access through COVID and beyond.
Watch Video
Access! 2021 – AAM Annual Meeting

May 26-27, 2021. Join us for the industry’s largest virtual conference. Access! convenes business leaders in the generics and biosimilars industry to get the inspiration, ideas and connections they need to drive their business forward.

Learn More
While We Await Vaccine Progress, We Can Trust in Generic Drugs

Read AAM CEO Dan Leonard's article on the essential role generic drugs play during the COVID-19, while we await a vaccine.

Read Blog
AAM’s Recommendations to #SecureOurMeds

AAM wrote to members of Congress, asking them to build on their previous successes and outlining key policy actions they can take to lower drug prices in the U.S.

Read Blog
Health Care Savings, State by State

The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?

Read Blog
Securing the U.S. Rx Supply Chain

The generic drug industry in the U.S. can expand domestically to increase national security, lessen dependence on any single country and create more jobs. Learn about our plan.

View Blueprint
Industry Response to COVID-19

The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.

Learn More

Working to leave a positive impact on...

Industry

We promote competition in the pharmaceutical industry by lowering barriers to entry for manufacturers of generic and biosimilar medicines and combatting anti-competitive abuses by some brand drug companies who put profits before patients. Learn More

People

We measure our success as an industry by the lives we impact. We work to protect the low cost of generic and biosimilar medicines and to drive down the cost of developing new ones, expanding access to as many people as possible. Learn More

Policy

We are a trusted partner and established authority within the pharmaceutical field. We provide accurate, timely data to educate policymakers and promote general public knowledge regarding the positive impact of affordable generic and biosimilar medicines. Learn More

About Us

The Association for Accessible Medicines improves access to safe, quality, effective medicine. Better access to medicine is relevant to everybody because, after all, we’re all patients at some point.

Health is the foundation for everything in life. Healthy people are better able to reach their full potential. Generics and biosimilars help more people in more places live healthier and longer.

Recent Updates

Video

Mar 4, 2021 | Erica Klinger

The Generics and Biosimilars Industry Has a Plan to Secure Our Medicines — #SecureOurMeds

Video

Mar 2, 2021 | Erica Klinger

Message from CEO Dan Leonard on Access! 2021

AAM Fit

Mar 2, 2021 | Erica Klinger

Healthy Competition in the Office—Even When We’re Not in the Office

American flag in Washington D.C.

Feb 25, 2021 | Rachel Schwartz

AAM Statement on President Biden’s Supply Chain Executive Order

AAM board room

Feb 24, 2021 | Rachel Schwartz

AAM Announces 2021 Board of Directors

AAM Lobby

Feb 24, 2021 | Rachel Schwartz

AAM Announces 2021 Associate Members